Michelle Lockhart - Project Management

Ms Lockhart has 10 years regulatory, marketing and clinical experience with Roche in both New Zealand and the UK. She also has six years project management experience with The Medicines Company. Michelle has been responsible for the regulatory and clinical programs at Antipodean since 2002. She has a Pharmacy degree and a Masters in management.


Michael Murphy, PhD - Research Director, Biology

Dr Murphy is group leader, Mitochondrial Dysfunction, MRC Dunn Human Nutrition Unit, Hills Road Cambridge, UK. He obtained an honors degree in Chemistry from Trinity College Dublin and a PhD in biochemistry from University of Cambridge. He held research and teaching appointments at Columbia University, New York; Trinity College, Dublin; and University of Otago, Dunedin. He was a visiting professor at the Biozentrum, University of Basel, Switzerland and the University of Alabama, Birmingham before being appointed associate dean for research at Otago University School of Medical Sciences. In 2001 his research group moved to the MRC Dunn Human Nutrition Unit.  Dr Murphy's research investigates how mitochondrial damage contributes to human diseases.


Robin Smith, PhD - Research Director, Chemistry

Dr Smith is Professor of Chemistry, University of Otago, an elected Fellow of the Royal Society of New Zealand, a Fellow of the New Zealand Institute of Chemistry and a Member of the Royal Society of Chemistry. After graduating from University of Otago with an honors degree and PhD in chemistry, he held academic research appointments in chemistry at Indiana University and Dartmouth College. Since 1971 he has been a faculty member of the Chemistry Department, University of Otago, Dunedin, New Zealand and has held Visiting Fellowships the Institut de Chimie des Substances Naturelles, Gif-sur-Yvette, France, Research School of Chemistry, Australian National University, Canberra, Australia and Department of Organic Chemistry, Bell Laboratories, AT & T, New Jersey. He has also held Visiting Professorships at the University of California, Santa Barbara and the University of Utah. His research area is synthetic organic chemistry with application to biological systems. Professor Smith directs the Antipodean Pharmaceuticals scientific team at Otago University which includes chemists, biochemists and pharmaceutical scientists.


We can access input from the following experts as required;

Kevin Moore, PhD, MACP, FRCP

Professor of Hepatology, University College. London. Dr. Moore’s primary research interest is the role of oxidative and nitrosative stress in vascular function in health and disease.


Stephen A. Harrison, MD

Assistant Professor in the Department of Medicine in the Division of Gastroenterology, University of Texas Health Science Center, Chief of Hepatology at Brooke Army Medical Center in San Antonio. Dr. Harrison’s research interests include the mechanisms and significance of steatosis and chronic hepatitis C infection, treatments for non-alcoholic fatty liver disease, and the relationship between obesity, insulin resistance, and hepatitis C.


Antonio Vidal-Puig, MD, PhD, MRCP

Reader in Human Metabolism (Clinical), IMS Metabolic Research Laboratories, University of Cambridge.  Dr. Vidal-Puig’s research interest is the molecular mechanisms involved in insulin resistance, energy expenditure, fat deposition, and the mechanisms controlling the partition of energy towards oxidation or storage.


Jeffrey S. Glenn, MD. PhD

Assistant Professor, Medicine – Gastroenterology and Hepatology, Director, Center for Hepatitis and Liver Tissue Engineering, Stanford School of Medicine. Dr. Glenn’s primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies.